TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25636304

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (maximal dose 90 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23896810

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Younger age, shorter duration of illness, greater baseline symptom severity, shorter trial duration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: More study sites, fewer university or Veterans Affairs treatment settings, lower percentage of patients assigned to receive placebo
Number of subjects: 50
Study: 21563510

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy and acupoint stimulation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cognitive-behavior therapy
Number of subjects: 91
Study: 19304469

Group type: EXPERIMENTAL
Intervention: Ointment with high dosed herbal ingredients (verum)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo ointment (control)
Number of subjects: 32
Study: 16409423

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily continuously
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily on-demand
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily continuously
Number of subjects: 1902
Study: 15064010

Group type: EXPERIMENTAL
Intervention: Amifostine 200 mg/m2
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Amifostine 340 mg/m2
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Amifostine (both doses)
Number of subjects: 39
Study: 12084021

Group type: EXPERIMENTAL
Intervention: Training program for the prevention of lower back pain (LBP) including theoretical training on LBP, patient handling, and ergonomics, along with on-the-job ergonomics instruction.
Number of subjects: 136
Study: 11245023

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Surgery (R + S)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Surgery (S)
Number of subjects: 201
Study: 7608994

Group type: EXPERIMENTAL
Intervention: Coital alignment technique (19 women)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Directed masturbation (17 women)
Number of subjects: 36
Study: 2229527

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 20
Study: 79809

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 34
Study: 30261246

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for prevention of mobility disability
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Mass media advertisement for case finding
Number of subjects: 1566
Study: 27444262

Group type: EXPERIMENTAL
Intervention: Second-generation Femidom female condom (FC2)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Phoenurse female condom (PFC)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Comparison between PFC and FC2
Number of subjects: 290
Study: 24527444

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (1-2.5% in 40/60% O2/N2O mixture)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol anesthesia (infusion with remifentanil)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 44
Study: 22699673

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5% EMLA anesthetic cream
Number of subjects: 44
Study: 20357176

Group type: EXPERIMENTAL
Intervention: GnRH doses of 0, 2.5, 10, 25, 250, and 750 ng
Number of subjects: 16

Group type: COMPARATOR
Intervention: Transdermal testosterone clamp
Number of subjects: 16
Study: 17638108

Group type: EXPERIMENTAL
Intervention: Cancer survivors
Number of subjects: 968

Group type: COMPARATOR
Intervention: Non-cancer comparison group
Number of subjects: 968
Study: 16136044

Group type: EXPERIMENTAL
Intervention: Supplementary folic acid, fish oil, and calcium carbonate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 98
Study: 12186515

Group type: EXPERIMENTAL
Intervention: Oral vitamin K (1 mg, administered orally)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Subcutaneous vitamin K (1 mg, administered subcutaneously)
Number of subjects: 51
Study: 10329812

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 micrograms twice daily
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 220 micrograms twice daily
Number of subjects: 399

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 168 micrograms twice daily
Number of subjects: 399

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 336 micrograms twice daily
Number of subjects: 399
Study: 7795345

Group type: EXPERIMENTAL
Intervention: Prone sleeping position
Number of subjects: 43

Group type: COMPARATOR
Intervention: Supine sleeping position
Number of subjects: 43
Study: 1951878

Group type: EXPERIMENTAL
Intervention: Nutritional support (refeeding after 24 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Starvation for 24 hours
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High ODC activity in tumor tissue
Number of subjects: 70
Study: 7328224

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30759784

Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid (ALA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 29101333

Group type: EXPERIMENTAL
Intervention: delta‐9‐THC (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 26611777

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1500 mg of dalbavancin
Number of subjects: 698

Group type: COMPARATOR
Intervention: 2-dose regimen of dalbavancin (1000 mg IV on day 1 followed by 500 mg IV one week later)
Number of subjects: 698

Group type: COMPARATOR
Intervention: 2-dose regimen of dalbavancin
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1500 mg of dalbavancin in MRSA patients
Number of subjects: 698

Group type: COMPARATOR
Intervention: 2-dose regimen of dalbavancin in MRSA patients
Number of subjects: 698
Study: 25172481

Group type: EXPERIMENTAL
Intervention: Sleep group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wakefulness group
Number of subjects: 30
Study: 22167662

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg with FOLFIRI
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg with FOLFIRI
Number of subjects: 370
Study: 20141248

Group type: EXPERIMENTAL
Intervention: Carriers of the Asp40 allele of the OPRM1 gene
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Carriers of the long allele (≥7 tandem repeats) of the DRD4
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Carriers of the DRD4-L allele
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-reported vigor and urge to drink
Number of subjects: 112
Study: 17430378

Group type: EXPERIMENTAL
Intervention: Pulsed 532-nm KTP laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pulsed 595-nm PDL
Number of subjects: 15
Study: 15849806

Group type: EXPERIMENTAL
Intervention: CYP1A1 Ile‐Val substitution in exon 7
Number of subjects: 16

Group type: COMPARATOR
Intervention: CYP1A1 MspI polymorphisms
Number of subjects: 16

Group type: COMPARATOR
Intervention: CYP2E1 RsaI polymorphisms
Number of subjects: 16

Group type: COMPARATOR
Intervention: GSTM1 null type
Number of subjects: 16

Group type: COMPARATOR
Intervention: GSTT1 null type
Number of subjects: 16

Group type: COMPARATOR
Intervention: GSTP1 Ile104Val
Number of subjects: 16
Study: 12227681

Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg o.d. orally for 4 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nifedipine (as comparator antihypertensive drug)
Number of subjects: 25
Study: 10223595

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam plus tobramycin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ceftazidime plus tobramycin
Number of subjects: 300
Study: 8682007

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 1444664

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 80
Study: 3881561

Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CMFPT (CMFP plus tamoxifen)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CMFP and CMFPT groups combined)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Tamoxifen (added to CMFP)
Number of subjects: 265
Study: 30028352

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinic
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 53
Study: 28489682

Group type: EXPERIMENTAL
Intervention: Standard care + prehabilitation (motivational interview, high-intensity endurance training, promotion of physical activity)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 125
Study: 26360146

Group type: EXPERIMENTAL
Intervention: Stand-alone anterior lumbar interbody fusion (ALIF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both ALIF and TDR
Number of subjects: 50
Study: 26206373

Group type: EXPERIMENTAL
Intervention: PRONTO simulation training
Number of subjects: 15
Study: 22898251

Group type: EXPERIMENTAL
Intervention: dietary weight loss with a 10% weight loss goal (N=118)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: moderate‐to‐vigorous intensity aerobic exercise for 45 min/day, 5 days/week (n=117)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: both dietary weight loss and exercise (n=117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: control (n=87)
Number of subjects: 439
Study: 20655559

Group type: EXPERIMENTAL
Intervention: Flomoxef 1 g administered immediately before surgery
Number of subjects: 370

Group type: COMPARATOR
Intervention: Flomoxef 1 g administered twice daily for a total of 4 days from the day of surgery to postoperative day 3
Number of subjects: 370
Study: 18256922

Group type: EXPERIMENTAL
Intervention: GnRH agonist ovulation trigger
Number of subjects: 0
Study: 17166989

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg taken in the evening
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12715418

Group type: COMPARATOR
Intervention: Low calorie diet (1000 kcal below daily energy requirement, 1200-1500 kcal per day, 5-6 meals a day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low calorie diet + acupuncture (one cycle of six-week acupuncture procedures, 12 procedures total)
Number of subjects: 69
Study: 10766181

Group type: EXPERIMENTAL
Intervention: murine IgG2a mAb 17‐1A (500mg single infusion followed by 100mg four times every 4 weeks)
Number of subjects: 83
Study: 9149186

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m. + Amoxicillin 1 g t.i.d. + Metronidazole 250 mg t.i.d. (first 2 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. + Amoxicillin 1 g t.i.d. + Metronidazole 250 mg t.i.d. (last 2 weeks)
Number of subjects: 78
Study: 8381089

Group type: EXPERIMENTAL
Intervention: Inhaled nedocromil sodium (Tilade)
Number of subjects: 4723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4723
Study: 3315592

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intravenous APSAC
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reperfused patients (either agent)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-reperfused patients (either agent)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase and intravenous APSAC
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reperfused patients
Number of subjects: 93
Study: 31361318

Group type: EXPERIMENTAL
Intervention: Higher tacrolimus concentrations
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Lower serum magnesium trajectory
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Lower serum magnesium, age, and body mass index
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: HNF1β SNP rs752010 G > A
Number of subjects: 167

Group type: COMPARATOR
Intervention: No association between HNF1β SNPs and PTDM
Number of subjects: 167
Study: 30053811

Group type: EXPERIMENTAL
Intervention: DENV-specific immunoglobulin G (IgG) antibodies testing using Anti-dengue IgG ELISA
Number of subjects: 701

Group type: COMPARATOR
Intervention: Mosquito control measures
Number of subjects: 701

Group type: COMPARATOR
Intervention: Low income
Number of subjects: 701

Group type: COMPARATOR
Intervention: Sleeping outdoors
Number of subjects: 701
Study: 30296367

Group type: EXPERIMENTAL
Intervention: Training in the school of diabetic patients, provided with special literature and self-monitoring blood glucose diary (n = 45)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Training in the school of diabetic patients, provided with relevant literature and under active control (telephone calls, visits to the center) (n = 46)
Number of subjects: 148
Study: 25126527

Group type: EXPERIMENTAL
Intervention: Curcumin gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triamcinolone Acetonide gel
Number of subjects: 60
Study: 22503139

Group type: EXPERIMENTAL
Intervention: Greater loneliness
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Increased loneliness
Number of subjects: 524
Study: 20924676

Group type: EXPERIMENTAL
Intervention: SMS monitoring and compliance intervention
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Two-question questionnaire for non-adherence assessment
Number of subjects: 244
Study: 17503877

Group type: EXPERIMENTAL
Intervention: Nutritional supplements (vitamin C, vitamin E, flavonoids, L-carnitine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional supplements (various including antioxidants and amino acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study: 15857429

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg/day added to carbamazepine (CBZ)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 12165828

Group type: COMPARATOR
Intervention: 4 mg ondansetron (Group A, n = 29)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 5 mg tropisetron (Group B, n = 31)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (Group C, n = 27)
Number of subjects: 87
Study: 9419782

Group type: EXPERIMENTAL
Intervention: Tocolytics
Number of subjects: 23
Study: 3389978

Group type: EXPERIMENTAL
Intervention: Placental albumin (1.5 g/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Plasmatic albumin (1.5 g/kg)
Number of subjects: 51
Study: 31436310

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol administered by a bedside nurse anaesthetist
Number of subjects: 2

Group type: COMPARATOR
Intervention: Midazolam sedation administered by the endoscopic team
Number of subjects: 2
Study: 31263284

Group type: EXPERIMENTAL
Intervention: Pasteurized A. muciniphila supplementation
Number of subjects: 40
Study: 29362599

Group type: EXPERIMENTAL
Intervention: Dialyzable leukocyte extract (DLE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24593291

Group type: EXPERIMENTAL
Intervention: Chinese five-element music therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine lifestyles (Control)
Number of subjects: 71
Study: 23132848

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 34
Study: 21552053

Group type: EXPERIMENTAL
Intervention: Hemorrhoid laser procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 60
Study: 19118825

Group type: EXPERIMENTAL
Intervention: Acupuncture (Ac) during IVF treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: IVF with no Ac (Control)
Number of subjects: 67
Study: 16728231

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment (controls)
Number of subjects: 80
Study: 15226097

Group type: COMPARATOR
Intervention: Calibrated Automated Thrombogram (CAT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ProC Global (PCG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coagulation Inhibitor Potential (CIP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CIP assay ROC analysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: PCG assay ROC analysis
Number of subjects: 48
Study: 11324365

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Side position
Number of subjects: 40
Study: 9469625

Group type: EXPERIMENTAL
Intervention: Argatroban (60 mg/d for the first 2 days, then 10 mg twice daily for 5 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 7962996

Group type: EXPERIMENTAL
Intervention: Expert listeners judging dissimilarity of pathological voices with respect to breathiness and roughness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unidimensional ratings of breathiness and roughness by a second group of listeners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judgments of roughness influenced by the degree of breathiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differences in listener focus on voice quality aspects
Number of subjects: 0
Study: 2658450

Group type: EXPERIMENTAL
Intervention: hGH at a weekly dosage of 0.5 IU/kg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: hGH at a weekly dosage of 1.0 IU/kg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combined administration of 0.5 IU/kg/week hGH and a small amount of anabolic steroid
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Methionyl-hGH
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Methionine-free-hGH
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 203
Study: 810767

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline theophyllinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31466474

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, naproxen, diclofenac, ibuprofen, and selective cyclooxygenase 2 inhibitors such as celecoxib.
Number of subjects: 0
Study: 30840633

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide 0.8 ng/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide 0.6 ng/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Number of subjects: 60
Study: 28827237

Group type: EXPERIMENTAL
Intervention: Laryngopharyngeal endoscopic esthesiometer and rangefinder (LPEER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPEER
Number of subjects: 0
Study: 26000301

Group type: EXPERIMENTAL
Intervention: Exercise (EX; 60% VO2peak)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sedentary (CON)
Number of subjects: 17
Study: 23406026

Group type: EXPERIMENTAL
Intervention: Neurostimulation plus medical therapy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Neurostimulation
Number of subjects: 251

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 251
Study: 22828986

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle manoeuvre (IPM)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No Pringle manoeuvre (NPM)
Number of subjects: 126
Study: 18842671

Group type: EXPERIMENTAL
Intervention: High bicarbonate concentration (35 mmol/l)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High calcium concentration (1.50 mmol/l)
Number of subjects: 21
Study: 17502632

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (9-month multilevel intervention)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study: 15206638

Group type: EXPERIMENTAL
Intervention: Independent and staffed residential settings
Number of subjects: 0
Study: 11591981

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 14 mmHg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Gasless technique
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pneumoperitoneum at 10 mmHg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-hepatobiliary laparoscopic procedures
Number of subjects: 93
Study: 9751938

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 0
Study: 7999486

Group type: EXPERIMENTAL
Intervention: ephedrine 1 mg min‐1 (group E1: n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ephedrine 2 mg min‐1 (group E2: n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: phenylephrine 10 micrograms min‐1 (group P: n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: phenylephrine 10 micrograms min‐1 with bolus doses of 20 micrograms
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ephedrine 1 or 2 mg min‐1 with bolus doses of 6 mg
Number of subjects: 29
Study: 3288946

Group type: EXPERIMENTAL
Intervention: Single dose trimethoprim-sulfamethoxazole
Number of subjects: 132

Group type: COMPARATOR
Intervention: 3-day regimen of trimethoprim-sulfamethoxazole
Number of subjects: 132

Group type: COMPARATOR
Intervention: 7-day regimen of trimethoprim-sulfamethoxazole
Number of subjects: 132
Study: 30962423

Group type: EXPERIMENTAL
Intervention: Cortisol administration after extinction training (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo administration after extinction training (n = 25)
Number of subjects: 50
Study: 29197407

Group type: EXPERIMENTAL
Intervention: Low tidal volume (LTV) ventilation: 5 breaths/minute with a tidal volume of 3 mL/kg and positive end-expiratory pressure of 5 cmH2O
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No ventilation (noV) during CPB
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Low tidal volume (LTV) ventilation
Number of subjects: 1500
Study: 25873548

Group type: EXPERIMENTAL
Intervention: Typical voice
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dysphonic voice
Number of subjects: 93